William Blair Reiterates "Market Perform" Rating for Zealand Pharma A/S (OTCMKTS:ZLDPF)

Key Points

• William Blair reiterated a "market perform" rating on Zealand Pharma, while analyst coverage is split (four Strong Buy, four Hold), leaving a MarketBeat consensus rating of "Buy."
• Zealand posted Q results with EPS of ($0.81) that beat the ($1.34) estimate but revenue of $10.79M missed the $19.69M consensus; the stock trades at a low P/E of 4.22 and a market cap of $4.10B.
• The company's pipeline is led by dasiglucagon, a stable glucagon analog for emergency treatment of severe hypoglycemia, reflecting its focus on metabolic and endocrine disorders.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s stock had its "market perform" rating restated by analysts at William Blair in a research report issued on Friday.

ZLDPF has been the subject of a number of other reports. Cantor Fitzgerald reiterated a "neutral" rating on shares of Zealand Pharma A/S in a research note on Friday. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th. Finally, BTIG Research upgraded Zealand Pharma A/S to a "strong-buy" rating in a research note on Friday, November 28th. Four investment analysts have rated the stock with a Strong Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Zealand Pharma A/S presently has a consensus rating of "Buy".

Zealand Pharma A/S Price Performance

ZLDPF stock opened at $57.67 on Friday. The stock has a fifty day moving average of $64.96 and a 200-day moving average of $70.77. Zealand Pharma A/S has a fifty-two week low of $49.98 and a fifty-two week high of $101.29. The company has a market capitalization of $4.10 billion, a price-to-earnings ratio of 4.22 and a beta of 0.75. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.10 and a current ratio of 14.10.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its earnings results on Thursday, February 19th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.34) by $0.53. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 49.76%. The firm had revenue of $10.79 million during the quarter, compared to the consensus estimate of $19.69 million. As a group, equities research analysts predict that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand's pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.